Blueprint Medicines Corpo... (BPMC)
84.14
-0.55 (-0.65%)
At close: Apr 21, 2025, 3:59 PM
84.21
0.08%
Pre-market: Apr 22, 2025, 04:06 AM EDT
Blueprint Medicines Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | 27.63M | 24.04M | 3.59M | 125.26M | 39.88M | 39.07M | 30.06M | 8.96M | 6.69M | 6.31M | 5.68M | 3.46M |
| Collaboration and License Revenue Growth | +14.94% | +569.51% | -97.13% | +214.13% | +2.07% | +29.95% | +235.72% | +33.90% | +6.02% | +11.06% | +64.26% | n/a |
| Product Revenue | 128.18M | 114.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +12.33% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| Non-Us Revenue | 22.24M | 13.77M |
| Non-Us Revenue Growth | +61.52% | n/a |
| United States Revenue | 181.97M | 97.23M |
| United States Revenue Growth | +87.16% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 96.45M | 89.93M | 89.34M | 83.56M | 79.27M | 70.74M | 71.93M | 70.95M | 64.02M | 57.61M | 58.69M | 57.06M | 54.2M | 49.81M | 49.29M | 42M | 42.54M | 37.38M | 42.17M | 35.66M | 32.27M | 25.65M | 21.92M | 16.55M | 13.64M | 12.04M | 12.33M | 9.91M | 8.09M | 7.38M | 6.83M | 5.68M | 4.99M | 4.89M | 4.69M | 4.65M | 3.62M | 4.22M | 3.84M | 2.77M |
| Selling, General, and Administrative Revenue Growth | +7.25% | +0.66% | +6.92% | +5.41% | +12.06% | -1.65% | +1.38% | +10.83% | +11.13% | -1.84% | +2.86% | +5.28% | +8.82% | +1.06% | +17.34% | -1.27% | +13.82% | -11.38% | +18.28% | +10.51% | +25.80% | +16.99% | +32.44% | +21.33% | +13.30% | -2.37% | +24.44% | +22.48% | +9.68% | +7.98% | +20.24% | +13.86% | +2.00% | +4.37% | +0.90% | +28.20% | -14.16% | +9.95% | +38.63% | n/a |
| Research and Development Revenue | 83.67M | 85.3M | 80.65M | 83.38M | 96.01M | 110.25M | 110.06M | 112.07M | 117.84M | 127.98M | 128.47M | 103.13M | 356.88M | 84.42M | 80.03M | 79.71M | 77.41M | 74.23M | 91.08M | 84.15M | 88.65M | 81.45M | 87.1M | 74.25M | 70.53M | 64.56M | 58.57M | 49.95M | 43.63M | 39.3M | 33.27M | 28.49M | 24.07M | 18.15M | 21.27M | 17.64M | 16.43M | 11.68M | 11.24M | 9.23M |
| Research and Development Revenue Growth | -1.91% | +5.76% | -3.27% | -13.15% | -12.92% | +0.17% | -1.79% | -4.89% | -7.92% | -0.38% | +24.56% | -71.10% | +322.74% | +5.49% | +0.40% | +2.98% | +4.28% | -18.50% | +8.24% | -5.08% | +8.83% | -6.48% | +17.31% | +5.27% | +9.25% | +10.22% | +17.25% | +14.50% | +11.02% | +18.12% | +16.79% | +18.34% | +32.63% | -14.68% | +20.63% | +7.32% | +40.67% | +3.90% | +21.78% | n/a |
| Sales and Marketing Revenue | 30.23M | 26.74M | 22.71M | 16.93M | 16.9M | 13.07M | 18.72M | 10.05M | 18.1M | 7.72M | n/a | n/a | 13.5M | n/a | n/a | n/a | 6.89M | n/a | n/a | n/a | 3.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +13.03% | +17.76% | +34.13% | +0.18% | +29.29% | -30.17% | +86.26% | -44.48% | +134.49% | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |